MARKET

REGN

REGN

Regeneron Pharmaceuticals
NASDAQ
784.97
+1.26
+0.16%
After Hours: 785.14 +0.17 +0.02% 17:58 12/26 EST
OPEN
783.79
PREV CLOSE
783.71
HIGH
788.01
LOW
778.04
VOLUME
321.04K
TURNOVER
--
52 WEEK HIGH
792.77
52 WEEK LOW
475.17
MARKET CAP
82.50B
P/E (TTM)
18.79
1D
5D
1M
3M
1Y
5Y
1D
Regeneron (REGN): Revisiting Valuation After Japan’s Dupixent Pediatric Asthma Approval and Bullish Investor Positioning
Simply Wall St · 1d ago
Medicare pilot programs aim to reduce prescription drug spend
Seeking Alpha · 2d ago
Sanofi, Regeneron’s Dupixent approved in Japan for children with asthma
Seeking Alpha · 3d ago
Regeneron, Sanofi get marketing authorization for Dupixent from MHLW in Japan
TipRanks · 3d ago
Sanofi And Regeneron's Dupixent Wins Japan Nod For Pediatric Asthma
NASDAQ · 3d ago
Dupixent Approval In Japan Expands Treatment Of Bronchial Asthma To Children Aged 6 To 11 Years Following Global Phase 3 VOYAGE And EXCURSION Data
Benzinga · 3d ago
Sanofi: Dupixent Now Approved In Japan For Children Aged 6 To 11 Years
NASDAQ · 3d ago
BRIEF-Sanofi And Regeneron's Dupixent Approved In Japan For Children With Bronchial Asthma
Reuters · 3d ago
More
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Webull offers Regeneron Pharmaceuticals Inc stock information, including NASDAQ: REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.